Consensus statements	Level	Grade
•HCC surveillance can detect early tumors that are potentially amenable to treatment; hence, all patients at higher risk of developing HCC and who are eligible for HCC therapy are candidates for regular HCC surveillance.	I	Strong
•Level of awareness of physicians managing patients of chronic liver disease is a major factor in surveillance of HCC; there is a need for greater healthcare provider awareness to improve HCC surveillance.	III	Strong
• Following patients should be subjected to surveillance for HCC: ∘ Patients with cirrhosis ▪ Child's A and B cirrhotic patients of any etiology ▪ Child's C cirrhotic patients of any etiology who are listed for liver transplantation ∘ Patients without cirrhosis ▪ Patients with chronic hepatitis B who have increased risk for HCC according to risk scores such as CU-HCC or PAGE-B ▪ Chronic HCV with advanced fibrosis.	I	Strong
•Six-monthly ultrasound abdomen by experienced personnel plus AFP level is the recommended surveillance test.	I	Strong